


AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) ~~The invention relates to a group of novel phenylpiperazine derivatives~~ A compound of the formula (I):



wherein:


- X is 1) a group of the formula



wherein


- S_1 is hydrogen or halogen,
- S_2 and S_3 are independently hydrogen, alkyl (1-6C), phenyl or benzyl,
- S_4 represents two hydrogen atoms or an oxo group,
- S_5 is H or alkyl (1-4C), and
- Y is $[[C]]$ \underline{CH}_2 , O or S,

or 2) a group of the formula




wherein S_1 has the above meaning and R is H, alkyl (1-4C), alkoxyalkyl (2-6C), alkenyl (2-4C) or alkynyl (2-4C),

or 3) a group of the formula




wherein S_1 has the above meaning and Z is $[[C]] \underline{CH_2}$, O or $[[N]] \underline{NH}$,

or 4) a group of the formula




wherein S_1 has the above meaning,

or 5) a group of the formula




wherein S_1 has the above meaning and A is O or $[[N]] \underline{NH}$, linked to the piperazine ring with position 5 or 8,

or 6) a group of the formula



wherein S_1 has the above meaning and S_6 and S_7 represent hydrogen atoms or an oxo group,

or 7) a group of the formula



wherein one of the dotted lines can represent a double bond, S₁ has the above meaning, and

$P=T=Q=$ P, T, and Q are independently nitrogen or NH

or $P=T=$ P and T are independently nitrogen or NH and Q [= C] is CH or CH₂

or $P=Q=$ P and Q are independently nitrogen or NH and T = C or C-CH₃ is CH, CH₂, C-CH₃ or CH-CH₃


or ~~$P=$ nitrogen, and T and Q are carbon~~

or P [=] is nitrogen or NH, T is carbon CH or CH₂ and Q is sulphur


- m has the value 2 to 6;
 - n has the value 0-2;
 - R₅ and R₆ are independently H or alkyl (1-3C); or R₅+R₆ represent a group -(CH₂)_p wherein p has the value 3-5, and
 - R₇ is alkyl (1-3C), alkoxy (1-3C), halogen or cyano; or R₆+R₇ (R₇ at position 7 of the indole group) represent a group -(CH₂)_q wherein q has the value 2-4,
- and salts an enantiomer thereof, or a salt of any of the foregoing.

2. (Previously Presented) A compound as claimed in claim 1, wherein X represents a group of the formula (1), (2) or (3), wherein the symbols have the meanings given in claim 1, an enantiomer thereof, or a salt of any of the foregoing.

3. (Currently Amended) A compound as claimed in claim 1, wherein X is the group having formula ~~(I)~~ (1), wherein $S_1=S_3=S_5=H$, $S_4=oxo$ and $S_2=CH_3$, m is 3, $R_5=R_6=H$, n is 0 or 1, and R_7 is 5-fluoro, ~~and salts~~ an enantiomer thereof, or a salt of any of the foregoing.
4. (Currently Amended) Method A method ~~for the preparation of compounds preparing a compound, an enantiomer thereof, or a salt of any of the foregoing~~ as claimed in claim 1, ~~characterised in that~~ comprising reacting a compound having formula (II)



~~is reacted~~ under basic conditions with a compound having formula (III)



in which formulae the symbols having the meanings given in claim 1, and L is a ~~so-called~~ leaving group,

to yield the compound, the enantiomer thereof, or the salt of any of the foregoing as claimed in claim 1.

5. (Currently Amended) A pharmaceutical composition ~~containing~~ comprising at least one compound as claimed in claim 1, an enantiomer thereof, or a salt of any of the foregoing as an active component and at least one auxiliary substance.
6. (Currently Amended) A method of preparing a composition as claimed in claim 5, ~~characterised in that a~~ comprising mixing the at least one compound, an enantiomer thereof, or a salt of any of the foregoing of claim 1 is brought into a form suitable for administration with the at least one auxiliary substance.
7. (Currently Amended) A method of treating ~~CNS disorders, characterised in that a~~ at least one central nervous system disorder in a human or animal patient in need of such treating, comprising administering at least one compound as claimed in claim 1, an enantiomer thereof, a salt of any of the foregoing, or a combination of the foregoing is used to the patient in an amount effective for the treating,
wherein the at least one central nervous system disorder is chosen from aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition, disturbances of memory, Parkinson's disease, schizophrenia, and psychotic disorders.
8. (New) The method of claim 7, in which the at least one central nervous system disorder is chosen from schizophrenia.

9. (New) A method of treating at least one central nervous system disorder in a human or animal patient in need of such treating, comprising administering at least one compound as claimed in claim 1, an enantiomer thereof, a salt of any of the foregoing, or a combination of the foregoing to the patient in an amount effective for the treating,
- wherein the at least one central nervous system disorder is caused by a disturbance in the dopaminergic or serotonergic systems.